Flagship Pioneering, LLC Long-Term Concentrated

Location: Cambridge, MA

CIK: 0001400240 · Show all filings

Period: Q3 2018 (← Previous) (Next →)

Filing Date: Nov 13, 2018

Total Value: $1.513B (100.0% shares, 0.0% debt)

Holdings (6)

— RUBIUS THERAPEUTICS INC 60.7%

Value $919M Shares 38,296,526 Est. Cost $24.00 Unrealized —

— EVELO BIOSCIENCES INC 14.7%

Value $222M Shares 18,233,403 Est. Cost $11.80 Unrealized —

DNLI DENALI THERAPEUTICS INC 12.8%

Value $194M Shares 8,918,749 Est. Cost $17.97 Unrealized -8.0%

— SERES THERAPEUTICS INC 6.4%

Value $96.26M Shares 12,682,876 Est. Cost $12.29 Unrealized —

QTRX QUANTERIX CORP 2.9%

Value $43.49M Shares 2,030,495 Est. Cost $19.52 Unrealized -19.0%

— SYROS PHARMACEUTICALS INC 2.5%

Value $38.16M Shares 3,204,437 Est. Cost $13.87 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	RUBIUS THERAPEUTICS INC	38,296,526	$919M	60.7%	$24.00	—	COM	78116T103
—	EVELO BIOSCIENCES INC	18,233,403	$222M	14.7%	$11.80	—	COM	299734103
DNLI	DENALI THERAPEUTICS INC	8,918,749	$194M	12.8%	$17.97	-8.0%	COM	24823R105
—	SERES THERAPEUTICS INC	12,682,876	$96.26M	6.4%	$12.29	—	COM	81750R102
QTRX	QUANTERIX CORP	2,030,495	$43.49M	2.9%	$19.52	-19.0%	COM	74766Q101
—	SYROS PHARMACEUTICALS INC	3,204,437	$38.16M	2.5%	$13.87	—	COM	87184Q107